Cytosorbents (CTSO) Net Income (2010 - 2026)

Cytosorbents has reported Net Income for 17 years, with the latest figure at -$3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income fell 163.87% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at -$17.8 million (down 11.6% YoY), and the FY2025 full-year result was -$9.2 million, up 55.56% from the prior year.
• Net Income for Q1 2026 stood at -$3.9 million, up from -$6.5 million in the prior quarter.
• The five-year high for Net Income was $15.3 million in Q4 2023, with the low at -$12.2 million in Q3 2022.
• Historically, Net Income has averaged -$4.7 million across 5 years, with a median of -$6.1 million in 2024.
• Annual changes were most pronounced in 2023 — Net Income surged 2102.15% — and 2026, when it sank 163.87%.
• Cytosorbents' Net Income stood at -$766126.0 in 2022, then surged by 2102.15% to $15.3 million in 2023, then sank by 149.33% to -$7.6 million in 2024, then increased by 14.02% to -$6.5 million in 2025, then soared by 40.04% to -$3.9 million in 2026.
• The last three Net Income figures came in at -$3.9 million (Q1 2026), -$6.5 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.